ATI LPN
Pharmacology and the Nursing Process 10th Edition Test Bank
Chapter 32 : Diabetes Drugs Questions
Question 1 of 5
A patient with a history of chronic obstructive pulmonary disease (COPD) and type 2 diabetes has been treated for pneumonia for the past week. The patient has been receiving intravenous corticosteroids as well as antibiotics as part of his therapy. At this time, the pneumonia has resolved, but when monitoring the blood glucose levels, the nurse notices that the level is still elevated. What is the best explanation for this elevation?
Correct Answer: B
Rationale: Corticosteroids increase blood glucose by inducing insulin resistance and stimulating gluconeogenesis. Antibiotics, COPD hypoxia, or type 1 conversion are not the primary causes.
Question 2 of 5
The nurse knows to administer acarbose, an alpha-glucosidase inhibitor, at which time?
Correct Answer: B
Rationale: Acarbose is taken with the first bite of each main meal to inhibit carbohydrate digestion, reducing postprandial glucose spikes.
Question 3 of 5
A patient has been diagnosed with metabolic syndrome and is started on the biguanide metformin. The nurse knows that the purpose of the metformin, in this situation, is which of these?
Correct Answer: B
Rationale: Metformin reduces insulin resistance by decreasing hepatic glucose production and improving insulin sensitivity in tissues, beneficial for metabolic syndrome.
Question 4 of 5
When administering morning medications for a newly admitted patient, the nurse notes that the patient has an allergy to sulfa drugs. There is an order for the sulfonylurea glipizide (Glucotrol). Which action by the nurse is correct?
Correct Answer: B
Rationale: Sulfa drug allergies may cross-react with sulfonylureas like glipizide, so the nurse must verify the order with the prescriber to ensure safety.
Question 5 of 5
The nurse is reviewing a patient's medication list and notes that sitagliptin (Januvia) is ordered. The nurse will question an additional order for which drug or drug class?
Correct Answer: B
Rationale: Sitagliptin, a DPP-4 inhibitor, is not typically combined with insulin due to lack of established safety and efficacy. It can be used with metformin, sulfonylureas, or glitazones.